|
|
Volumn 11, Issue 6, 2012, Pages 426-428
|
|
Can next-generation antibodies offset biosimilar competition?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BEVACIZUMAB;
CETUXIMAB;
CYTOTOXIN;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
GOLIMUMAB;
INFLIXIMAB;
MOGAMULIZUMAB;
MONOCLONAL ANTIBODY;
OCRELIZUMAB;
PERTUZUMAB;
RANIBIZUMAB;
RITUXIMAB;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
VASCULOTROPIN INHIBITOR;
BRAIN CANCER;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CLINICAL PRACTICE;
COLON CANCER;
COLORECTAL CANCER;
CROHN DISEASE;
DRUG APPROVAL;
DRUG CHOICE;
DRUG COST;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
HUMAN;
KIDNEY CANCER;
LUNG CANCER;
METASTASIS;
MONOTHERAPY;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROTEIN TARGETING;
RHEUMATOID ARTHRITIS;
SHORT SURVEY;
STRATEGIC PLANNING;
TREATMENT INDICATION;
ANTIBODIES, MONOCLONAL;
DRUG APPROVAL;
DRUG DISCOVERY;
DRUG INDUSTRY;
EUROPE;
HUMANS;
LEGISLATION, DRUG;
THERAPEUTIC EQUIVALENCY;
|
|
EID: 84861876412
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3749 Document Type: Short Survey |
|
Times cited : (36)
|
|
References (0)
|
